FDA official logo
GSRS logo
PFDA official logo

POLATUZUMAB VEDOTIN

  • UNII: KG6VO684Z6
  • Preferred Substance Name: POLATUZUMAB VEDOTIN

  • 1313206-42-6
  • ACD79B-VCMMAE
  • ACD-79BVCMMAE
  • ACD-79B-VCMMAE
  • ANTI-CD79B ADC
  • ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ANTI-CD79B-VC-MMAE
  • ANTI-CD79B MONOCLONAL ANTIBODY CONJUGATED TO MONOMETHYL AURISTATIN E (MMAE)
  • DCDS4501A
  • DCDS-4501A
  • FCU2711
  • FCU-2711
  • IMMUNOGLOBULIN G1-KAPPA AURISTATIN E CONJUGATE, ANTI-(HOMO SAPIENS CD79B (IMMUNOGLOBULIN-ASSOCIATED CD79 BETA)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN E
  • POLATUZUMAB VEDOTIN [INN]
  • POLATUZUMAB VEDOTIN [JAN]
  • POLATUZUMAB VEDOTIN [MI]
  • POLATUZUMAB VEDOTIN [USAN]
  • POLATUZUMAB VEDOTIN [WHO-DD]
  • POLATUZUMAB VEDOTIN PIIQ [WHO-DD]
  • POLATUZUMAB VEDOTIN-PIIQ
  • POLIVY
  • RG7596
  • RG-7596
  • RO5541077-000
  • RO-5541077000
  • RO-5541077-000

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.




About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

Powered by

DNAnexus official logo